Target Price | $11.27 |
Price | $2.91 |
Potential |
287.17%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Editas Medicine, Inc. 2025 .
The average Editas Medicine, Inc. target price is $11.27.
This is
287.17%
register free of charge
$23.00
690.38%
register free of charge
$3.00
3.09%
register free of charge
|
|
A rating was issued by 19 analysts: 10 Analysts recommend Editas Medicine, Inc. to buy, 9 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2025 of
287.17%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 78.12 | 26.28 |
296.35% | 66.36% | |
EBITDA Margin | -208.81% | -969.64% |
81.26% | 364.37% | |
Net Margin | -213.14% | -919.88% |
84.12% | 331.58% |
17 Analysts have issued a sales forecast Editas Medicine, Inc. 2024 . The average Editas Medicine, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2024. The average Editas Medicine, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Editas Medicine, Inc. Analysts have issued a net profit forecast 2024. The average Editas Medicine, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.02 | -2.93 |
37.07% | 45.05% | |
P/E | negative | |
EV/Sales | negative |
7 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Editas Medicine, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Editas Medicine, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.